Official Title: “Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes”

This trial is conducted in Europe. The purpose of the trial is to investigate the efficacy of liraglutide to induce body weight loss.

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: April 2009

Intervention(s) in this Clinical Trial

• Drug: liraglutide
• Drug: orlistat

Primary Measures

• Body weight loss
  • Time Frame: after 20 weeks of treatment
    Safety Issue?: No

Secondary Measures

• Glucose metabolism
  • Safety Issue?: No
• Cardiovascular risk factors
  • Safety Issue?: No
• Body composition
  • Safety Issue?: No

Inclusion Criteria:

• Body Mass Index (BMI) greater than or equal to 30.0 or lesser than or equal to 40.0 kg/m2
• Stable body weight (less than 5% selfreported change within the last 3 months)

Exclusion Criteria:

• Obesity induced by drug treatment
• Use of approved drugs for weight lowering intervention (e.g. orlistat, sibutramin, rimonabant) within the last 3 months prior to entering trial
• Type 1 or type 2 diabetes

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Lead Sponsor: Novo Nordisk

Overall Clinical Trial Officials and Contacts

Mads F. Rasmussen, MD, PhD Study Director Novo Nordisk  

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00422058

Study ID Number: NN8022-1807

ClinicalTrials.gov Identifier: NCT00422058

Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory

Clinical Trials at Novo Nordisk